Brief: Dicot Pharma Signs Agreement With CRO Ahead Of Phase 2B Study With Lib-01
18/12/2025 08:33
Dec 18 (Reuters) - Dicot Pharma AB DICOT.ST: SIGNS AGREEMENT WITH CRO AHEAD OF PHASE 2B STUDY WITH LIB-01 STUDY WILL BE CONDUCTED IN US AND EUROPE AND IS EXPECTED TO START DURING SECOND HALF OF 2026. Source text: ID:nMFN9sCwY0 Further company coverage: DICOT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dicot Pharma AB
See all newsBrief: Dicot Pharma Recruits Cecilia Driving As CFO
Brief: Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.
Brief: Dicot Pharma Announces Outcome In Oversubscribed Rights Issue
Brief: Dicot Pharma Announces Prelim Rights Issue Outcome
Brief: Dicot Pharma Submits IND Application To FDA